medsci Medical Sciences Med. Sci. Medical Sciences 2076-3271 MDPI 10.3390/medsci4030014 medsci-04-00014 Review Neuroprotection by Endoplasmic Reticulum Stress-Induced HRD1 and Chaperones: Possible Therapeutic Targets for Alzheimer’s and Parkinson’s Disease Nomura Jun 1 Hosoi Toru 2 Kaneko Masayuki 3 Ozawa Koichiro 2 Nishi Akinori 4 Nomura Yasuyuki 4 * Piccini Paola Academic Editor RIKEN Brain Research Institute, Saitama 351-0198, Japan; Jun.nomura@riken.jp Department of Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan; toruh@hiroshima-u.ac.jp (T.H.); ozawak@hiroshima-u.ac.jp (K.O.) Department of Biochemistry, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan; mkaneko@hiroshima-u.ac.jp Department of Pharmacology, Kurume University School of Medicine, Kurume 830-0011, Japan; nishia@med.kurume-u.ac.jp Correspondence: nomura_yasuyuki@kurume-u.ac.jp; Tel.: +81-942-31-7545 18 08 2016 09 2016 4 3 14 25 02 2016 15 08 2016 © 2016 by the authors; licensee MDPI, Basel, Switzerland. 2016

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).

Alzheimer’s disease (AD) and Parkinson’s disease (PD) are neurodegenerative disorders with a severe medical and social impact. Further insights from clinical and scientific studies are essential to develop effective therapies. Various stresses on the endoplasmic reticulum (ER) cause unfolded/misfolded proteins to aggregate, initiating unfolded protein responses (UPR), one of which is the induction of neuronal cell death. Some of the pathogenic factors for AD and PD are associated with UPR. ER molecules such as ubiquitin ligases (E3s) and chaperones are also produced during UPR to degrade and refold aberrant proteins that accumulate in the ER. In this review, we examine the role of HMG-CoA reductase degradation protein 1 (HRD1) and the chaperone protein-disulfide isomerase (PDI), which are both produced in the ER in response to stress. We discuss the importance of HRD1 in degrading amyloid precursor protein (APP) and Parkin-associated endothelin receptor-like receptor (Pael-R) to protect against neuronal death. PDI and the chemical chaperone 4-phenyl-butyrate also exert neuroprotective effects. We discuss the pathophysiological roles of ER stress, UPR, and the induction and neuroprotective effects of HRD1 and PDI, which may represent significant targets for novel AD and PD therapies.

 endoplasmic reticulum unfolded protein responses HRD1 molecular chaperone degradation/refolding of misfolded proteins Alzheimer’s disease Parkinson’s disease therapeutic development 1. Introduction

The prevalence of dementia is estimated to be approximately 25,000,000 people worldwide and is increasing exponentially as the number of senescent individuals increase. More than half of dementia patients have Alzheimer’s disease (AD). Another serious neurodegenerative disease is Parkinson’s disease (PD). Medical and social therapies are required for both diseases. Elucidating the pathogenic mechanisms underlying AD and PD is essential for treatment and will pave the way for the development of novel therapeutics.

Several genes are known to be involved in familial AD and PD, while epigenetic contributions to the pathogenesis have not yet been elucidated. A number of environmental, biological, chemical, and physical factors can cause pathological states. Metabolic abnormalities associated with diabetes mellitus type II and atherosclerosis/hyperlipidemia have been implicated in AD and PD. Hypertension has also been identified as a risk factor. Although the pathogenesis of neurodegeneration involves a complex combination of genetic and epigenetic factors, a common mechanism may be neuronal death in the brain. Therefore, the cerebral vascular systems in the supply of glucose and oxygen and the astroglial and microglial cells in the maintenance of neurons, have important roles in preventing neurodegeneration.

Stress to the endoplasmic reticulum (ER) caused by disrupted Ca2+ homeostasis, glucose starvation, hypoxia, and oxidative stress including hyperhomocysteinemia [1,2,3] can lead to cell death [4,5,6]. ER stress also induces the accumulation of unfolded/misfolded proteins, which may elicit unfolded protein responses (UPR) through intracellular signaling pathways [7]. Previous studies have suggested that UPR are closely involved in the pathogenesis of AD and PD [8,9].

In this review, we examine the role of HMG-CoA reductase degradation protein 1 (HRD1), which is a ubiquitin E3 ligase, and that of the molecular chaperone protein-disulfide isomerase (PDI) in AD and PD. These proteins are all produced in the ER in response to stress. We discuss the therapeutic significance of HRD1, PDI, and chemical chaperones in treating neurodegenerative diseases.

 2. ER Stress and UPR

The ER regulates intracellular Ca2+ concentrations, maturation of protein structures, and has crucial functions in the quality control of proteins. The accumulation of unfolded/misfolded proteins in the ER in response to stress induces the UPR, activating stress-related molecules such as inositol-requiring enzymes 1 (IRE1), activating transcription factor 6 (ATF6), and double-stranded RNA-activated protein kinase (PKR)-like ER kinase (PERK). Active IRE1 splices the X-box binding protein 1 (XBP1), which induces ER-resident chaperones (Figure 1).

A cleaved fragment of ATF6 (p50) and eIF2α phosphorylated by PERK also induces ER chaperones such as 78 kDa glucose-regulated protein (GRP78). Phosphorylated eIF2α also suppresses the biosynthesis of new proteins and the induction of cellular apoptosis (Figure 1) [4,10,11]. C/EBP-homologous protein (CHOP) genes are induced by phosphorylated eIF2α [12] and may be involved in apoptosis [13]. Furthermore, tribbles-related protein 3 (TRB3) was recently identified as a CHOP-inducible gene involved in cell death [14]. Additionally, the excessive/unfavorable accumulation of unfolded proteins leads to apoptotic cell death through the IRE1-TRAF2-ASK1-JNK pathway (Figure 1) [15]. ER-associated protein degradation (ERAD) is also involved in an UPR (Figure 1). The ER copes with aberrant proteins by ubiquitination and 26S proteasomal degradation. Cytoplasmic chaperones, such as heat shock proteins (HSP) HSP70 and HSP90, refold aberrant proteins. These ER functions may be important for cell survival. Several studies have suggested that disrupted activation of ER stress by a mutation in the presenillin gene downregulates the UPR and is involved in the pathogenesis of AD [16,17].

We previously identified two UPR-induced proteins: the E3 ubiquitin ligase HRD1 [18,19] and the molecular chaperone PDI [20]. In this review, we describe the cellular and molecular functions of these proteins. HRD1 and PDI play crucial roles in neuronal survival by acting as an E3 ubiquitin ligase and a molecular chaperone and may be involved in the pathogenesis of AD and PD (Figure 1). HRD1 and PDI may represent efficient tools in the pharmacological intervention of neurodegenerative diseases and are potential targets for novel AD and PD therapies.

 3. HRD1: Identification and Characterization

We previously identified and cloned the human ER stress-responsive protein HRD1. In combination with the ubiquitin-activating enzyme E1 and the ubiquitin-associating enzyme E2, E3 catalyzes the ubiquitination and degradation of denatured/unfolded proteins. HRD1 binds, ubiquitinates, and degrades APP, reducing the formation of amyloid (Aβ) plaques [18,19,21].

Several UPR genes have been identified in the yeast Saccharomyces cerevisiae [22]. In an attempt to isolate and identify novel human UPR genes, we previously focused on the ERAD genes Hrd1p/Der3p, which exhibit E3 activity and are localized in the ER of yeast. Using bioinformatics, we identified human KIAA 1810 from the protein library that possessed an amino acid sequence with high homology to the Hrd1p protein in yeast. We cloned this protein and named and characterized it as described below [18,19].

Human HRD1 is ubiquitously expressed in the brain (CA1, substantia nigra, and Purkinje cells), lungs, liver, pancreas, kidneys, and skeletal muscle of mice. It is also expressed in the CA1 and CA4 regions of the human hippocampus and is not expressed in astroglial cells. HRD1 exhibits E3 ubiquitin ligase activity and exerts protective effects against ER stress-induced cell death [23].

Hypoxic stress promotes HRD1 expression in the cerebral cortex and striatum [24], implicating HRD1 in the response to and suppression of ER stress in the brain. Treating HEK293 cells with ER stress inducers (thapsigargin (a sarco/reticulum Ca2+-ATPase inhibitor) or tunicamycin (an N-glycosylation inhibitor)) markedly increases HRD1 expression [18,19]. HRD1 mRNA expression in HEK293 cells are regulated by IRE1 pathways [25], which has also been demonstrated in yeast.

 4. AD and HRD1

Two main hypotheses have been proposed for the pathology of AD: the Aβ hypothesis and the phosphorylated tau (P-tau) hypothesis. The Aβ hypothesis is based on the histological evidence of senile plaques and accumulation of Aβ, whereas the P-tau hypothesis is based on the appearance of neurofibrillary tangles and accumulation of the P-tau protein in the brain [26,27].

4.1. Aβ Hypothesis

Among several hypotheses on the pathogenesis of AD, the Aβ hypothesis has been well received [28] but is not yet generally accepted [29]. Aβ, composed mainly of Aβ1–40 and Aβ1–42, is generated from APP by the peptidase enzymes, β-secretase and γ-secretase [30,31,32,33,34]. Aβ induces the formation of oligomers, which leads to neuronal death [35,36,37,38]. To develop novel therapeutics for AD, extensive efforts have been made to identify molecules that can target and reduce the levels of Aβ, including γ-secretase inhibitors and vaccines against Aβ [39,40,41,42,43]. These efforts have not been successful, but the implantation of microglia/microglia-like cells into local areas of the brain may reduce Aβ levels 1–42 in vivo [44,45]. Novel therapeutic targets or strategies are urgently needed.

 4.2. HRD1: APP Ubiquitination and Reduction in the AD Brain

We previously reported that HRD1 colocalizes with APP in mouse neurons, binds APP at proline-rich regions of HRD1, and ubiquitinates and degrades APP [21,46]. Overexpression of HRD1 reduces the generation of Aβ1–40 and Aβ1–42. In contrast, the suppression of HRD1 expression by small interfering RNA (siRNA) induces APP accumulation and neuronal death (Figure 2) [21].

In addition, the generation of Aβ1–40 and Aβ1–42 (Figure 2) is significantly enhanced. Thus, HRD1 ubiquitinates and degrades denaturated APP as well as unfolded proteins, suggesting that HRD1 affects APP-Aβ dynamics in the brains of AD patients.

It has not yet been established whether HRD1 functions normally in the AD brain. Solubilized HRD1 protein (by 1% NP-40 detergent) levels are lower in the postmortem cerebral cortex of AD patients than in the non-AD controls [21,46]. It was previously shown that HRD1 expression correlates negatively with Aβ1–40 and Aβ1–42 [47]. Although this study was limited regarding the number of specimens and consideration of the clinical states, these findings suggest that HRD1 participates in reducing Aβ levels, thereby suppressing the pathogenesis of AD. In contrast to the decreased soluble HRD1 protein levels in AD, HRD1 mRNA expression has been shown to increase, suggesting a secondary compensation for the reduced protein levels. We aimed to clarify the mechanism of HRD1 protein insolubilization in the brain of AD patients; we examined whether Aβ, tau, ER stress, or oxidative stress, which are associated with AD pathology, induce HRD1 insolubilization. We found that oxidative stress causes insolubilization of HRD1 protein but not other AD-related stresses (Aβ, tau, and ER stress) [48]. Therefore, oxidative stress-induced HRD insolubilization may be involved in Aβ accumulation and in the pathogenesis of AD.

Further studies are required to determine whether HRD1 ubiquitinates and degrades phosphorylated tau proteins [49].

 5. PD, HRD1, and Chaperones

PD is a common neurodegenerative disease with a movement disorder, particularly in the elderly. The pathological hallmark of PD is the loss of dopamine (DA)-containing neurons in the substantia nigra pars compacta (SNC), reducing DA levels in the striatum.

5.1. Role of ER Stress in the Pathogenesis of PD

Most cases of PD are sporadic, and an estimated 5%–10% of patients are monogenic. The genes involved in autosomal recessive PD are Parkin (PARK2), PINK1 (PARK6), DJ1 (PARK7), and ATP13A2 (PARK9). The genes involved in autosomal dominant PD are α-synuclein (PARK 1/4), LRRK2 (PARK8), and UCHL-1 (PARK5) [50,51]. LRRK2 and α-synuclein are common risk factors for sporadic PD and have been identified as substrates for ERAD-related ubiquitin ligase E3. Furthermore, changes in ERAD-related E3, C-terminus of HSP70-interacting protein (CHIP), and Parkin levels have demonstrated that disturbances in the ERAD system are responsible for the onset of PD [52,53,54,55]. Thus, ER stress may be a causative factor for PD.

Parkin is an E3 ubiquitin ligase and ubiquitinates its own substrate, the misfolded Parkin-associated endothelin receptor-like receptor (Pael-R), suppressing cell death caused by the accumulation of Pael-R [56]. Parkin mutations reduce E3 activity, which leads to the accumulation of unfolded Pael-R and ER stress-induced cell death. Therefore, ER stress caused by the accumulation of Pael-R is relevant to the pathological mechanisms underlying autosomal recessive PD.

Previous studies have shown that Parkin-deficient mice exhibited no significant changes in dopaminergic neurodegeneration or the accumulation of Parkin substrates [57,58,59]. However, Parkin-knockout/Pael-R transgenic mice exhibited fewer dopaminergic neurons [60], suggesting that other E3s degrade accumulated Pael-R in the absence of Parkin as a compensatory mechanism. The co-operation of PINK1 and Parkin in the treatment of damaged mitochondrial degradation has already been reported [61,62]. Autophosphorylated PINK1 recruits Parkin to degrade damaged mitochondria. However, in PD, these events are averted by PINK1 mutations. These findings implicate E3 Parkin in the onset of PD.

 5.2. HRD1 and PD

We previously demonstrated that HRD1 is expressed in the SNC, particularly in DA-containing neurons [63]. Pael-R is also expressed in DA neurons of the SNC. We showed that HRD1 and Pael-R colocalize in the ER of dopaminergic SH-SY5Y cells. Pael-R binds to and is ubiquitinated by HRD1. The reduction of endogenous HRD1 by siRNA causes leads to the accumulation of Pael-R and activation of caspase-3. This demonstrates that Pael-R is also a substrate for HRD1 and Parkin [64]. We reported that Pael-R-induced cell death was suppressed by the overexpression of HRD1. α-synuclein is not a substrate of HRD1; therefore, HRD1 may be involved in the onset of PD through Pael-R but not through α-synuclein.

 5.3. PDI, Chemical Chaperones, and PD

Molecular chaperones function in protein quality control, for example in the folding of misfolded/unfolded proteins that accumulate in the ER under stressful conditions such as oxidation and/or mutated gene products [65,66,67]. Molecular chaperones are essential for cell survival. Stress causes unfolded proteins to accumulate in the ER, which induces molecular chaperones such as Bip, calnexin, glucose-regulated protein 94 (GRP94), and PDI. We previously demonstrated the upregulation of PDI in response to hypoxia/brain ischemia and its protective effects against hypoxia/ischemia-induced apoptotic cell death [20]. These findings suggest that PDI suppresses the onset of Pael-R-related PD.

5.3.1. PDI

PDI prevents thapsigargin- and tunicamycin-dependent neuronal apoptosis, suggesting that PDI suppresses ER stress-induced neuronal death [63,68]. PDI also inhibits MG132 (proteasomal inhibitor)-induced cell death, which indicates that protein ubiquitination and degradation participates in cell death [69]. A previous study reported that PDI suppresses Pael-R-induced neuronal death, suggesting that PDI functions as a chaperone to alleviate and rescue neuronal death in PD [69].

PDI catalyzes a thiol-disulphide exchange reaction that facilitates disulphide bond formation and a rearrangement reaction. In the PDI molecule, four cysteines form thioredoxin-like domains, which are involved in catalytic reactions. Although S-nitrosylation has been proposed as a physiological signal for neuronal nitric oxide [70], these cysteines are nitrosylated by NO donors, reducing the catalytic activity. We previously reported an increase in SNO-PDI levels in postmortem brains of AD and PD patients [69]. Yao et al. identified a relationship between nitrosative stress and sporadic PD [71]. Thus, the physiological and pathophysiological roles of cerebral nitric oxide have already been demonstrated. The S-nitrosylation of PDI may be involved in neuronal death, contributing to AD and PD pathogenesis [69].

 5.3.2. Chemical Chaperones

Chemical chaperones stabilize proteins and ameliorate the accumulation of unfolded proteins [72,73] to attenuate ER stress. Glycerol, dimethylsulfoxide (DMSO), and 4-phenyl-butyrate (4-PBA) have been identified as chemical chaperones. 4-PBA has been employed in clinical trials for sickle-cell anemia [74], β-thalassemia [75], and cystic fibrosis [76]. We previously demonstrated that 4-PBA promoted the correct folding of unfolded Pael-R and suppressed cell death caused by Pael-R accumulation [77,78]. A synthetic derivative of 4-PBA, 4-(4-methoxyphenyl)butanoic acid was better at inhibiting protein aggregation and ER stress-induced neuronal death than 4-PBA [79]. Tauroursodeoxycholic acid (TUDCA) is a chemical chaperone that inhibits Aβ-induced cell death [80,81,82]. However, the therapeutic effects of chemical chaperones for AD and PD have only been investigated in vitro so far.

 6. Potential Therapeutic Strategies for AD and PD

In this review, we suggest that alleviators of ER stress and suppressors of ER stress-induced neuronal cell death represent potential therapeutic targets for AD and PD (Figure 3).

HRD1 and molecular chaperones against AD and PD are possible candidates for the discovery of therapeutics against neurodegenerative diseases. Induction of molecular chaperones would be one of the useful strategies for ameliorating the diseases. Interestingly, BiP inducer X (BIX) was shown to protect against neuronal cell death caused by ER stress by inducing the molecular chaperone, GRP78 [83]. Furthermore, chemical chaperones, which can reduce aggregated protein accumulation may be also beneficial for the treatments. However, considering the usage of such a kind of drugs, there currently have no evidence for the clinical use without side effects. Therefore, future analysis may be required for elucidating such compounds. Moreover, protein antioxidants and NO inhibitors may also be efficient against AD and PD. Autophagy, another protein degradation pathway in addition to ubiquitination, has potential as a target for novel AD and PD therapies [84,85,86].

Molecules that decrease and/or deplete Aβ and α-synuclein are currently being investigated. A vaccine against Aβ has not yet been successfully developed, but an injection of microglial/microglia-like cells into the brain appears to remove Aβ [44,45]. Peptide synthesis of pathogenic Aβ1–42 oligomer aggregate inhibitors may be successful [87]. It is important to identify patients with mild cognitive impairment during early stages of the disease, and this requires probes for neuroimaging and suitable clinical biomarkers. Further efforts are needed to develop both therapeutics and prophylactics.

We are hopeful that a local injection of iPS cells with the potential to differentiate into acetylcholine- or DA-containing neurons into pathological regions of the hippocampus or substantia nigra will successfully treat the symptoms of neurodegenerative diseases in the future.

 7. Conclusions

ER stress/UPR may be involved in the pathogenesis of AD and PD. Therefore, HRD1 and PDI represent promising targets for the development of novel AD and PD therapies. In addition, chemical chaperones are potential therapeutic candidates for these diseases. Currently, development of drugs targeting unfolded proteins are still in the nascent stage. Furthermore, there are no clinically useful drugs that can modify activity of HRD1 and PDI. We believe that development of these drugs will be a useful strategy for future treatment of AD and PD.

 Acknowledgments

We are grateful to Ezio Giacobini, Geneva University Hospitals, for his encouragement. We thank Yasunobu Okuma, Yoshihisa Kitamura, Takashi Uehara, Tomohiro Omura, Ryo Saito, and Seisuke Mimori for their excellent suggestions in the preparation of this manuscript. The present study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture, Japan.

 Conflicts of Interest

The authors declare no conflict of interest.

 References Seshadri S. Beiser A. Selhub J. Jacques P.F. Rosenberg I.H. D’Agostino R.B. Wilson P.W.F. Wolf P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease N. Engl. J. Med. 2002 346 476 483 10.1056/NEJMoa011613 11844848 Morris M.S. Homocysteine and Alzheimer’s disease Lancet Neurol. 2003 2 425 428 10.1016/S1474-4422(03)00438-1 Hosoi T. Ogawa K. Ozawa K. Homocysteine induces X-box-binding protein 1 splicing in the mice brain Neurochem. Int. 2010 56 216 220 10.1016/j.neuint.2009.12.005 20018221 Hosoi T. Nomura J. Ozawa K. Nishi A. Nomura Y. Possible involvement of endoplasmic reticulum stress in the pathogenesis of Alzheimer’s disease Endoplasm. Reticul. Stress Dis. 2015 2 107 118 10.1515/ersc-2015-0008 Paschen W. Mengesdorf T. Endoplasmic reticulum stress response and neurodegeneration Cell Calcium 2005 38 409 415 10.1016/j.ceca.2005.06.019 16087231 Ron D. Walter P. Signal integration in the endoplasmic reticulum unfolded protein response Nat. Rev. Mol. Cell Biol. 2007 8 519 529 10.1038/nrm2199 17565364 Sidrauski C. Chapman R. Walker P. The unfolded protein response: An intracellular signaling pathway with many surprising features Trends Cell Biol. 1998 8 245 249 10.1016/S0962-8924(98)01267-7 Omura T. Kaneko M. Okuma Y. Matsubara K. Nomura Y. Endoplasmic reticulum stress and Parkinson’s disease: The role of HRD1 in averting apoptosis in neurodegenerative disease Oxid. Med. Cell. Longev. 2013 2013 10.1155/2013/239854 23710284 Lindholm D. Wootz H. Korhonen L. ER stress and neurodegenerative diseases Cell Death Differ. 2006 13 385 392 10.1038/sj.cdd.4401778 16397584 Hosoi T. Ozawa K. Endoplasmic reticulum stress in disease: Mechanisms and therapeutic opportunities Clin. Sci. 2009 118 19 29 10.1042/CS20080680 19780718 Walter P. Ron D. The unfolded protein response: From stress pathway to homeostatic regulation Science 2011 334 1081 1086 10.1126/science.1209038 22116877 Harding H.P. Novoa I. Zhang Y. Zeng H. Wek R. Schapira M. Ron D. Regulated translation initiation controls stress-induced gene expression in mammalian cells Mol. Cell 2000 6 1099 1108 10.1016/S1097-2765(00)00108-8 Zinszner H. Kuroda M. Wang X. Batchvarova N. Lightfoot R.T. Remotti H. Stevens J.L. Ron D. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum Genes Dev. 1998 12 982 995 10.1101/gad.12.7.982 9531536 Ohoka N. Yoshii S. Hattori T. Onozaki K. Hayashi H. TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death EMBO J. 2005 24 1243 1255 10.1038/sj.emboj.7600596 15775988 Nishitoh H. Matsuzawa A. Tobiume K. Saegusa K. Takeda K. Inoue K. Hori S. Kakizuka A. Ichijo H. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats Genes Dev. 2002 16 1345 1355 10.1101/gad.992302 12050113 Katayama T. Imaizumi K. Honda A. Yoneda T. Kudo T. Takeda M. Mori K. Rozmahel R. Fraser P. St. George-Hyslop P. Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer’s disease-linked presenilin-1 mutations J. Biol. Chem. 2001 276 43446 43454 10.1074/jbc.M104096200 11551913 Katayama T. Imaizumi K. Sato N. Miyoshi K. Kudo T. Hitomi J. Morihara T. Yoneda T. Gomi F. Mori Y. Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response Nat. Cell Biol. 1999 1 479 485 10.1038/70265 10587643 Kaneko M. Ishiguro M. Niinuma Y. Uesugi M. Nomura Y. Human HRD1 protects against ER stress-induced apoptosis through ER-associated degradation FEBS Lett. 2002 532 147 152 10.1016/S0014-5793(02)03660-8 Kaneko M. Nomura Y. ER signaling in unfolded protein response Life Sci. 2003 74 199 205 10.1016/j.lfs.2003.09.007 14607247 Tanaka S. Uehara T. Nomura Y. Up-regulation of protein-disulfide isomerase in response to hypoxia/brain ischemia and its protective effect against apoptotic cell death J. Biol. Chem. 2000 275 10388 10393 10.1074/jbc.275.14.10388 10744727 Kaneko M. Koike H. Saito R. Kitamura Y. Okuma Y. Nomura Y. Loss of HRD1-mediated protein degradation causes amyloid precursor protein accumulation and amyloid-beta generation J. Neurosci. 2010 30 3924 3932 10.1523/JNEUROSCI.2422-09.2010 20237263 Travers K.J. Patil C.K. Wodicka L. Lockhart D.J. Weissman J.S. Walter P. Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation Cell 2000 101 249 258 10.1016/S0092-8674(00)80835-1 Omura T. Kaneko M. Tabei N. Okuma Y. Nomura Y. Immunohistochemical localization of a ubiquitin ligase HRD1 in murine brain J. Neurosci. Res. 2008 86 1577 1587 10.1002/jnr.21616 18241051 Qi X. Okuma Y. Hosoi T. Kaneko M. Nomura Y. Induction of murine HRD1 in experimental cerebral ischemia Brain Res. Mol. Brain Res. 2004 130 30 38 10.1016/j.molbrainres.2004.07.013 15519674 Kaneko M. Yasui S. Niinuma Y. Arai K. Omura T. Okuma Y. Nomura Y. A different pathway in the endoplasmic reticulum stress-induced expression of human HRD1 and SEL1 genes FEBS Lett. 2007 581 5355 5360 10.1016/j.febslet.2007.10.033 17967421 Lee V.M. Goedert M. Trojanowski J.Q. Neurodegenerative tauopathies Annu. Rev. Neurosci. 2001 24 1121 1159 10.1146/annurev.neuro.24.1.1121 11520930 Hardy J. Selkoe D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics Science 2002 297 353 356 10.1126/science.1072994 12130773 Hardy J.A. Higgins G.A. Alzheimer’s disease: The amyloid cascade hypothesis Science 1992 256 184 185 10.1126/science.1566067 1566067 Herrup K. The case for rejecting the amyloid cascade hypothesis Nat. Neurosci. 2015 18 794 799 10.1038/nn.4017 26007212 De Strooper B. Saftig P. Craessaerts K. Vanderstichele H. Guhde G. Annaert W. von Figura K. van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein Nature 1998 391 387 390 10.1038/34910 9450754 Yan R. Bienkowski M.J. Shuck M.E. Miao H. Tory M.C. Pauley A.M. Brashier J.R. Stratman N.C. Mathews W.R. Buhl A.E. Membrane-anchored aspartyl protease with Alzheimer’s disease beta-secretase activity Nature 1999 402 533 537 10.1038/990107 10591213 Sinha S. Anderson J.P. Barbour R. Basi G.S. Caccavello R. Davis D. Doan M. Dovey H.F. Frigon N. Hong J. Purification and cloning of amyloid precursor protein beta-secretase from human brain Nature 1999 402 537 540 10.1038/990114 10591214 Zhang X. Li Y. Xu H. Zhang Y.W. The γ-secretase complex: From structure to function Front. Cell. Neurosci. 2014 8 10.3389/fncel.2014.00427 25565961 Vassar R. Kuhn P.H. Haass C. Kennedy M.E. Rajendran L. Wong P.C. Lichtenthaler S.F. Function, therapeutic potential and cell biology of BACE proteases: Current status and future prospects J. Neurochem. 2014 130 4 28 10.1111/jnc.12715 24646365 Pike C.J. Walencewicz A.J. Glabe C.G. Cotman C.W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity Brain Res. 1991 563 311 314 10.1016/0006-8993(91)91553-D Frautschy S.A. Baird A. Cole G.M. Effects of injected Alzheimer beta-amyloid cores in rat brain Proc. Natl. Acad. Sci. USA 1991 88 8362 8366 10.1073/pnas.88.19.8362 1924295 Loo D.T. Copani A. Pike C.J. Whittemore E.R. Walencewicz A.J. Cotman C.W. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons Proc. Natl. Acad. Sci. USA 1993 90 7951 7955 10.1073/pnas.90.17.7951 8367446 LaFerla F.M. Tinkle B.T. Bieberich C.J. Haudenschild C.C. Jay G. The Alzheimer’s A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice Nat. Genet. 1995 9 21 30 10.1038/ng0195-21 7704018 Golde T.E. Koo E.H. Felsenstein K.M. Osborne B.A. Miele L. γ-Secretase inhibitors and modulators Biochim. Biophys. Acta 2013 1828 2898 2907 10.1016/j.bbamem.2013.06.005 23791707 Imbimbo B.P. Giardina G.A. γ-secretase inhibitors and modulators for the treatment of Alzheimer’s disease: Disappointments and hopes Curr. Top. Med. Chem. 2011 11 1555 1570 10.2174/156802611795860942 21510832 Schenk D. Barbour R. Dunn W. Gordon G. Grajeda H. Guido T. Hu K. Huang J. Johnson-Wood K. Khan K. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 1999 400 173 177 10.1038/22124 10408445 Janus C. Pearson J. McLaurin J. Mathews P.M. Jiang Y. Schmidt S.D. Chishti M.A. Horne P. Heslin D. French J. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease Nature 2000 408 979 982 10.1038/35050110 11140685 Hock C. Konietzko U. Papassotiropoulos A. Wollmer A. Streffer J. von Rotz R.C. Davey G. Moritz E. Nitsch R.M. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease Nat. Med. 2002 8 1270 1275 10.1038/nm783 12379846 Takata K. Kitamura Y. Yanagisawa D. Morikawa S. Morita M. Inubushi T. Tsuchiya D. Chishiro S. Saeki M. Taniguchi T. Microglial transplantation increases amyloid-beta clearance in Alzheimer model rats FEBS Lett. 2007 581 475 478 10.1016/j.febslet.2007.01.009 17240371 Takata K. Takada T. Tatsuda H. Tsuruno T. Nishimura K. Shimohama S. Kitamura Y. Preparation and characterization of microglia-like cells derived from rat, mouse, and human bone marrow cells for therapeutic strategy of Alzheimer’s disease J. Addict. Res. Ther. 2011 10.4172/2155-6105.S5-001 Kaneko M. Okuma Y. Nomura Y. Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer’s disease: Possible involvement of HRD1, a novel molecule related to endoplasmic reticulum stress, in Alzheimer’s disease J. Pharmacol. Sci. 2012 118 325 330 10.1254/jphs.11R11FM 22382662 Saito R. Kaneko M. Okuma Y. Nomura Y. Correlation between decrease in protein levels of ubiquitin ligase HRD1 and amyloid-beta production J. Pharmacol. Sci. 2010 113 285 288 10.1254/jphs.10118SC 20606367 Saito R. Kaneko M. Kitamura Y. Takata K. Kawada K. Okuma Y. Nomura Y. Effects of oxidative stress on the solubility of HRD1, a ubiquitin ligase implicated in Alzheimer’s disease PLoS ONE 2014 9 e94576 10.1371/journal.pone.0094576 24788773 Shen Y.X. Sun A.M. Fang S. Feng L.J. Li Q. Hou H.L. Liu C. Wang H.P. Shen J.L. Luo J. Hrd1 facilitates tau degradation and promotes neuron survival Curr. Mol. Med. 2012 12 138 152 10.2174/156652412798889009 22280354 Tan E.K. Skipper L.M. Pathogenic mutations in Parkinson disease Hum. Mutat. 2007 28 641 653 10.1002/humu.20507 17385668 Abou-Sleiman P.M. Muqit M.M. Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson’s disease Nat. Rev. Neurosci. 2006 7 207 219 10.1038/nrn1868 16495942 Imai Y. Soda M. Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity J. Biol. Chem. 2000 275 35661 35664 10.1074/jbc.C000447200 10973942 Ding X. Goldberg M.S. Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP PLoS ONE 2009 4 e5949 10.1371/journal.pone.0005949 19536328 Ko H.S. Bailey R. Smith W.W. Liu Z. Shin J.-H. Lee Y.-I. Zhang Y.-J. Jiang H. Ross C.A. Moore D.J. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity Proc. Natl. Acad. Sci. USA 2009 106 2897 2902 10.1073/pnas.0810123106 19196961 Shimura H. Hattori N. Kubo S. Mizuno Y. Asakawa S. Minoshima S. Shimizu N. Iwai K. Chiba T. Tanaka K. Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase Nat. Genet. 2000 25 302 305 10888878 Imai Y. Soda M. Inoue H. Hattori N. Mizuno Y. Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin Cell 2001 105 891 902 10.1016/S0092-8674(01)00407-X Goldberg M.S. Fleming S.M. Palacino J.J. Cepeda C. Lam H.A. Bhatnagar A. Meloni E.G. Wu N. Ackerson L.C. Klapstein G.J. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons J. Biol. Chem. 2003 278 43628 43635 10.1074/jbc.M308947200 12930822 Itier J.M. Ibanez P. Mena M.A. Abbas N. Cohen-Salmon C. Bohme G.A. Laville M. Pratt J. Corti O. Pradier L. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse Hum. Mol. Genet. 2003 12 2277 2291 10.1093/hmg/ddg239 12915482 Perez F.A. Palmiter R.D. Parkin-deficient mice are not a robust model of parkinsonism Proc. Natl. Acad. Sci. USA 2005 102 2174 2179 10.1073/pnas.0409598102 15684050 Wang H.Q. Imai Y. Inoue H. Kataoka A. Iita S. Nukina N. Takahashi R. Pael-R transgenic mice crossed with parkin deficient mice displayed progressive and selective catecholaminergic neuronal loss J. Neurochem. 2008 107 171 185 10.1111/j.1471-4159.2008.05607.x 18691389 Matsuda N. Sato S. Shiba K. Okatsu K. Saisho K. Gautier C.A. Sou Y.S. Saiki S. Kawajiri S. Sato F. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy J. Cell Biol. 2010 189 211 221 10.1083/jcb.200910140 20404107 Okatsu K. Oka T. Iguchi M. Imamura K. Kosako H. Tani N. Kimura M. Go E. Koyano F. Funayama M. PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria Nat. Commun. 2012 3 10.1038/ncomms2016 22910362 Omura T. Kaneko M. Okuma Y. Orba Y. Nagashima K. Takahashi R. Fujitani N. Matsumura S. Hata A. Kubota K. A ubiquitin ligase HRD1 promotes the degradation of Pael receptor, a substrate of Parkin J. Neurochem. 2006 99 1456 1469 10.1111/j.1471-4159.2006.04155.x 17059562 Omura T. Kaneko M. Onoguchi M. Koizumi S. Itami M. Ueyama M. Okuma Y. Nomura Y. Novel functions of ubiquitin ligase HRD1 with transmembrane and proline-rich domains J. Pharmacol. Sci. 2008 106 512 519 10.1254/jphs.08005FP 18344614 Saibil H. Chaperone machines for protein folding, unfolding and disaggregation Nat. Rev. Mol. Cell Biol. 2013 14 630 642 10.1038/nrm3658 24026055 Kim I. Xu W. Reed J.C. Cell death and endoplasmic reticulum stress: Disease relevance and therapeutic opportunities Nat. Rev. Drug Discov. 2008 7 1013 1030 10.1038/nrd2755 19043451 Tyedmers J. Mogk A. Bukau B. Cellular strategies for controlling protein aggregation Nat. Rev. Mol. Cell Biol. 2010 11 777 788 10.1038/nrm2993 20944667 Ko H.S. Uehara T. Nomura Y. Role of ubiquilin associated with protein-disulfide isomerase in the endoplasmic-retilumin stress-induced apoptotic cell death J. Biol. Chem. 2002 277 35386 35392 10.1074/jbc.M203412200 12095988 Uehara T. Nakamura T. Yao D. Shi Z.-Q. Gu Z. Ma Y. Masliah E. Nomura Y. Lipton S.A. S-Nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration Nature 2006 441 513 517 10.1038/nature04782 16724068 Jaffrey S.R. Erdjument-Bromage H. Ferris C.D. Tempst P. Snyder S.H. Protein S-nitrosylation: A physiological signal for neuronal nitric oxide Nature Cell Biol. 2001 3 193 197 10.1038/35055104 11175752 Yao D. Gu Z. Nakamura T. Shi Z.-Q. Ma Y. Gaston B. Palmer L.A. Rockenstein E.M. Zhang Z. Masliah E. Nitrosative stress linked to sporadic Parkinson’s disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity Proc. Natl. Acad. Sci. USA 2004 101 10810 10814 10.1073/pnas.0404161101 15252205 Bernier V. Lagacé M. Bichet D.G. Bouvier M. Pharmacological chaperones: Potential treatment for conformational diseases Trends Endocrinol. Metab. 2004 15 222 228 10.1016/j.tem.2004.05.003 15223052 Ong D.S. Kelly J.W. Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases Curr. Opin. Cell Biol. 2011 23 231 238 10.1016/j.ceb.2010.11.002 21146391 Dover G.J. Brusilow S. Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate Blood 1994 84 339 343 7517215 Collins A.F. Pearson H.A. Giardina P. McDonagh K.T. Brusilow S.W. Dover G.J. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: A clinical trial Blood 1995 85 43 49 7528572 Rubenstein R.C. Zeitlin P.L. Use of protein repair therapy in the treatment of cystic fibrosis Am. J. Resp. Crit. Care Med. 1998 157 484 490 10.1164/ajrccm.157.2.9706088 9476862 Kubota K. Niinuma Y. Kaneko M. Okuma Y. Sugai M. Omura T. Uesugi M. Uehara T. Hosoi T. Nomura Y. Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress J. Neurochem. 2006 97 1259 1268 10.1111/j.1471-4159.2006.03782.x 16539653 Mimori S. Okuma Y. Kaneko M. Kawada K. Hosoi T. Ozawa K. Nomura Y. Hamana H. Protective effects of 4-phenylbutyrate derivatives on the neuronal cell death and endoplasmic reticulum stress Biol. Pharm. Bull. 2012 35 84 90 10.1248/bpb.35.84 22223342 Mimori S. Okuma Y. Kaneko M. Kawada K. Nomura Y. Murakami Y. Hamana H. Discovery of synthetic methoxy-substituted 4-phenylbutyric acid derivatives as chemical chaperones Chem. Lett. 2013 42 1051 1052 10.1246/cl.130419 Solá S. Castro R.E. Laires P.A. Steer C.J. Rodrigues C.M. Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway Mol. Med. 2003 9 226 234 10.2119/2003-00042.Rodrigues 15208744 Viana R.J. Nunes A.F. Castro R.E. Ramalho R.M. Meyerson J. Fossati S. Ghiso J. Rostagno A. Rodrigues C.M. Tauroursodeoxycholic acid prevents E22Q Alzheimer’s Abeta toxicity in human cerebral endothelial cells Cell. Mol. Life Sci. 2009 66 1094 1104 10.1007/s00018-009-8746-x 19189048 Ramalho R.M. Nunes A.F. Dias R.B. Amaral J.D. Lo A.C. D’Hooge R. Sebastião A.M. Rodrigues C.M. Tauroursodeoxycholic acid suppresses amyloid β-induced synaptic toxicity in vitro and in APP/PS1 mice Neurobiol. Aging 2013 34 551 561 10.1016/j.neurobiolaging.2012.04.018 22621777 Kudo T. Kanemoto S. Hara H. Morimoto N. Morihara T. Kimura R. Tabira T. Imaizumi K. Takeda M. A molecular chaperone inducer protects neurons from ER stress Cell Death Differ. 2008 15 364 375 10.1038/sj.cdd.4402276 18049481 Zhu X.C. Yu J.T. Jiang T. Tan L. Autophagy modulation for Alzheimer’s disease therapy Mol. Neurobiol. 2013 48 702 714 10.1007/s12035-013-8457-z 23625314 Harris H. Rubinsztein D.C. Control of autophagy as a therapy for neurodegenerative disease Nat. Rev. Neurol. 2011 8 108 117 10.1038/nrneurol.2011.200 22187000 Correia S.C. Moreira P.I. Perry G. Autophagy in Alzheimer’s disease: A cleaning service out-of-order? Toxicity and Autophagy in Neurodegenerative Disorders Fuentes J.M. Springer International Publishing Zurich, Switzerland 2015 Volume 9 123 142 Sohma Y. Medicinal chemistry focusing on aggregation of amyloid-β Chem. Pharm. Bull. 2016 64 1 7 10.1248/cpb.c15-00742 26726739 Figures

Unfolded protein responses and neurodegeneration. Unfolded protein responses related to endoplasmic reticulum (ER) stress and signaling pathways are shown. Each function positively and negatively affects the pathogenesis of neurodegeneration. ASK1: Apoptosis signal-regulating kinase 1; ATF: Activating transcription factor; ERAD: ER-associated degradation; CHOP: C/EBP-homologous protein; IRE1: Inositol-requiring enzymes 1; JNK: c-Jun N-terminal kinase; PERK: (PKR)-like ER kinase; TRAF2: TNF receptor-associated factor 2; XBP1: X-box binding protein 1;

Amyloid precursor protein (APP) accumulation, amyloid plaques (Aβ) generation, and neuronal apoptosis by HMG-CoA reductase degradation protein 1 (HRD1) suppression in SH-SY5Y cells. (A) Induction of APP accumulation by HRD1 siRNA. SH-SY5Y cells stably expressing APP-FLAG were analyzed by western blotting with the indicated antibodies; (B) Aβ40 and Aβ42 were measured by sandwich ELISA using the culture medium from (A). Statistical analysis was performed with ANOVA. * p < 0.05; ** p < 0.01; Con: control, NC: non-target control, HRD1: treatment with siRNA-HRD1; (C) Cell apoptosis after treatment with HRD1 siRNA. SH-SY5Y cells stably expressing APP-FLAG were transiently transfected with NC or siRNA-HRD1. The cells were subjected to immunofluorescence staining with anti-cleaved caspase-3 antibodies. Staining was analyzed statistically. The percentage of apoptotic cells in three different areas was calculated. * p < 0.05; ** p < 0.01. NC: non-target control, HRD1: treatment with siRNA-HRD1.

Strategies for developing therapeutics for neurodegenerative diseases. Protein antioxidants and upregulators of ubiquitin ligase E3 (e.g., HRD1) could be therapeutic targets for AD. Upregulators of molecular chaperones, inhibitors of nitrosylation of PDI, and chemical chaperones could be therapeutic targets for PD. In addition, alleviators of ER stress and suppressors of cell death could be therapeutic targets for neurodegenerative diseases. AD: Alzheimer’s disease, PD: Parkinson’s disease.